Diagnosis and management of hyponatremia in cancer patients

Supportive Care in Cancer

Volumn 15, Issue 12, 2007, Pages 1341-1347

  Raftopoulos, Harry ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Arginine vasopressin; AVP receptor antagonists; Hyponatremia; Malignancy; Syndrome of inappropriate secretion of antidiuretic hormone

Indexed keywords

ARGIPRESSIN DERIVATIVE; CONIVAPTAN; DEMECLOCYCLINE; FUROSEMIDE; LITHIUM; LIXIVAPTAN; SATAVAPTAN; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; UNCLASSIFIED DRUG;

CANCER PATIENT; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE CLASSIFICATION; EXTRACELLULAR FLUID; GASTROINTESTINAL SYMPTOM; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SERUM OSMOLALITY; SIDE EFFECT; SODIUM BLOOD LEVEL; SUPERINFECTION; SYMPTOM; THERAPY EFFECT; THIRST; TREATMENT OUTCOME; TREATMENT RESPONSE; UREMIA; URINE OSMOLALITY;

ARGININE VASOPRESSIN; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; NEOPLASMS; RECEPTORS, VASOPRESSIN; RISK FACTORS;

EID: 35948950703     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0309-9     Document Type: Review

References (50)

1. Adrogué HJ, Madias NE (2000) Hyponatremia. N Engl J Med 342:1581-1589
2. Anderson RJ, Chung H-M, Kluge R, Schrier RW (1985) Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 102:164-168
3. Bartter FC, Schwartz WB (1967) The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42:790-806
4. Baylis PH (1989) Regulation of vasopressin secretion. Baillieres Clin Endocrinol Metab 3:313-330
5. Baylis PH (2003) The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 35:1495-1499
6. Berghmans T (1996) Hyponatremia related to medical anticancer treatment. Support Care Cancer 4:341-350
7. Berghmans T, Paesmans M, Body JJ (1999) A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 8:192-197
8. Berry PL, Belsha CW (1990) Hyponatremia. Pediatr Clin North Am 37:351-363
9. Bissett D, Cornford EJ, Sokal M (1989) Hyponatraemia following cisplatin chemotherapy. Acta Oncol 28:823
10. Bliss DP Jr, Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE (1990) Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst 82:305-310
11. Boku N, Ohtsu A, Nagashima F, Muto M, Shinkai T, Yoshida A (2001) Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? Jpn J Clin Oncol 31:382-387
12. Campling BG, Sarda IR, Baer KA, Pang SC, Baker HM, Lofters WS, Flynn TG (1995) Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 75:2442-2451
13. Cancer Therapy Evaluation Program (2006) Common terminology criteria for adverse events, version 3.0. DCTD, NCI, NIH, DHHS; March 31, 2003. Available at: http://ctep.cancer.gov. Publish date: August 9, 2006. Accessed on November 15, 2006
14. Cao L, Joshi P, Sumoza D (2002) Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. Am J Clin Oncol 25:344-346
15. Comis RL, Miller M, Ginsberg SJ (1980) Abnormalities in water homeostasis in small cell anaplastic lung cancer. Cancer 45:2414-2421
16. Decaux G, Soupart A (2003) Treatment of symptomatic hyponatremia. Am J Med Sci 326:25-30
17. Dhaliwal HS, Rohatiner AZS, Gregory W, Richards MA, Johnson PWM, Whelan JS, Gallagher CJ, Matthews J, Ganesan TS, Barnett MJ, Waxman JH, Stansfeld AG, Wrigley PFM, Slevin ML, Malpas JS, Lister TA (1993) Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma. Br J Cancer 68:767-774
18. el Weshi A, Thieblemont C, Cottin V, Barbet N, Catimel G (1995) Cisplatin-induced hyponatremia and renal sodium wasting. Acta Oncol 34:264-265
19. Elisaf MS, Konstantinides A, Siamopoulos KC (1996) Chronic hyponatremia due to reset osmostat in a patient with colon cancer. Am J Nephrol 16:349-351
20. Ellis SJ (1995) Severe hyponatraemia: complications and treatment. QJM 88:905-909
21. Fried LF, Palevsky PM (1997) Hyponatremia and hypernatremia. Med Clin North Am 81:585-609
22. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 124:933-939
23. 2 antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91:2145-2152
24. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107:2690-2696
25. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C (2004) Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291:1963-1971
26. Glover DJ, Glick JH (1987) Metabolic oncologic emergencies. CA Cancer J Clin 37:302-320
27. Goh KP (2004) Management of hyponatremia. Am Fam Phys 69:2387-2394
28. Gross AJ, Steinberg SM, Reilly JG, Bliss DP Jr, Brennan J, Le PT, Simmons A, Phelps R, Mulshine JL, Ihde DC, Johnson BE (1993) Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 53:67-74
29. Gross P, Reimann D, Henschkowski J, Damian M (2001) Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 12:S10-S14
30. 2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia [abstract]. J Am Soc Nephrol 15:355A, Abstract SA-P0243
31. Gullans SR, Verbalis JG (1993) Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med 44:289-301
32. Iyer AV, Krasnow SH, Dufour R, Arcenas AS (2003) Sodium-wasting nephropathy caused by cisplatin in a patient with small-cell lung cancer. Clin Lung Cancer 5:187-189
33. Kinzie BJ (1987) Management of the syndrome of inappropriate secretion of antidiuretic hormone. Clin Pharm 6:625-633
34. Langfeldt LA, Cooley ME (2003) Syndrome of inappropriate antidiuretic hormone secretion in malignancy: review and implications for nursing management. Clin J Oncol Nurs 7:425-430
35. List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH (1986) The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 4:1191-1198
36. Nielsen S (2002) Renal aquaporins: an overview. BJU Int 90(Suppl 3):1-6
37. Østerlind K (1994) Factors confounding evaluation of treatment effect in lung cancer. Lung Cancer 10(Suppl 1):S97-S103
38. Palmer BF (2003) Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 14:182-187
39. Poe CM, Taylor LM (1989) Syndrome of inappropriate antidiuretic hormone: assessment and nursing implications. Oncol Nurs Forum 16:373-381
40. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G (2006) Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119:71.e1-71.e8
41. Robertson GL (2001) Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 30:671-694
42. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, for the SALT Investigators (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099-2112
43. Schwartz WB, Bennett W, Curelop S, Bartter FC (1957) A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23:529-542
44. Silverman P, Distelhorst CW (1989) Metabolic emergencies in clinical oncology. Semin Oncol 16:504-515
45. Sørensen JB, Andersen MK, Hansen HH (1995) Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 238:97-110
46. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G (2006) Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 1:634-640
47. Vanhees SL, Paridaens R, Vansteenkiste JF (2000) Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review. Ann Oncol 11:1061-1065
48. 2 receptor antagonists. J Mol Endocrinol 29:1-9
49. Wong F, Blei AT, Blendis LM, Thuluvath PJ (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 37:182-191
50. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N (2007) Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 27:447-457